AI assistant
Sending…
KALA BIO, Inc. — Director's Dealing 2017
Nov 21, 2017
35091_dirs_2017-11-21_af86540e-9d9d-4903-8e52-ba45c71079d8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-11-20
Reporting Person: Bazemore Todd (Chief Operating Officer)
More from KALA BIO, Inc.
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 15
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Capital/Financing Update
2026
Mar 4
Board/Management Information
2026
Feb 20
Major Shareholding Notification
2026
Feb 17
Capital/Financing Update
2026
Feb 9
Director's Dealing
2026
Feb 9
Director's Dealing
2026
Feb 9